BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dijckmeester WA, Wijnhoven BP, Watson DI, Leong MP, Michael MZ, Mayne GC, Bright T, Astill D, Hussey DJ. MicroRNA-143 and -205 expression in neosquamous esophageal epithelium following Argon plasma ablation of Barrett's esophagus. J Gastrointest Surg. 2009;13:846-853. [PMID: 19190970 DOI: 10.1007/s11605-009-0799-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Chisholm JA, Mayne GC, Hussey DJ, Watson DI. Molecular biomarkers and ablative therapies for Barrett's esophagus. Expert Rev Gastroenterol Hepatol 2012;6:567-81. [PMID: 23061708 DOI: 10.1586/egh.12.39] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
2 Hulf T, Sibbritt T, Wiklund ED, Patterson K, Song JZ, Stirzaker C, Qu W, Nair S, Horvath LG, Armstrong NJ, Kench JG, Sutherland RL, Clark SJ. Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene 2013;32:2891-9. [PMID: 22869146 DOI: 10.1038/onc.2012.300] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 6.6] [Reference Citation Analysis]
3 Mayne GC, Bright T, Hussey DJ, Watson DI. Ablation of Barrett's oesophagus: towards improved outcomes for oesophageal cancer? ANZ J Surg 2012;82:592-8. [PMID: 22901306 DOI: 10.1111/j.1445-2197.2012.06151.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Fassan M, Facchin S, Munari G, Fanelli GN, Lorenzon G, Savarino E. Noncoding RNAs as drivers of the phenotypic plasticity of oesophageal mucosa. World J Gastroenterol 2017; 23(43): 7653-7656 [PMID: 29209106 DOI: 10.3748/wjg.v23.i43.7653] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Bansal A, Lee IH, Hong X, Anand V, Mathur SC, Gaddam S, Rastogi A, Wani SB, Gupta N, Visvanathan M, Sharma P, Christenson LK. Feasibility of mcroRNAs as biomarkers for Barrett's Esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol 2011;106:1055-63. [PMID: 21407181 DOI: 10.1038/ajg.2011.37] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
6 Sreedharan L, Mayne GC, Watson DI, Bright T, Lord RV, Ansar A, Wang T, Kist J, Astill DS, Hussey DJ. MicroRNA profile in neosquamous esophageal mucosa following ablation of Barrett’s esophagus. World J Gastroenterol 2017; 23(30): 5508-5518 [PMID: 28852310 DOI: 10.3748/wjg.v23.i30.5508] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Lv J, Liu J, Guo L, Zhang J, Cheng Y, Chen C, Zhao H, Wang J. Bioinformatic analyses of microRNA-targeted genes and microarray-identified genes correlated with Barrett's esophagus. Cell Cycle 2018;17:792-800. [PMID: 29417867 DOI: 10.1080/15384101.2018.1431597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Mouillet JF, Chu T, Nelson DM, Mishima T, Sadovsky Y. MiR-205 silences MED1 in hypoxic primary human trophoblasts. FASEB J 2010;24:2030-9. [PMID: 20065103 DOI: 10.1096/fj.09-149724] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 8.1] [Reference Citation Analysis]
9 Shiotani A, Uedo N, Iishi H, Murao T, Kanzaki T, Kimura Y, Kamada T, Kusunoki H, Inoue K, Haruma K. H. pylori eradication did not improve dysregulation of specific oncogenic miRNAs in intestinal metaplastic glands. J Gastroenterol. 2012;47:988-998. [PMID: 22382634 DOI: 10.1007/s00535-012-0562-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
10 Chen H, Fang Y, Tevebaugh W, Orlando RC, Shaheen NJ, Chen X. Molecular mechanisms of Barrett's esophagus. Dig Dis Sci 2011;56:3405-20. [PMID: 21984436 DOI: 10.1007/s10620-011-1885-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
11 Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J, Hussey DJ. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg. 2011;15:429-438. [PMID: 21246413 DOI: 10.1007/s11605-011-1418-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 6.6] [Reference Citation Analysis]
12 Lai VK, Ashraf M, Jiang S, Haider K. MicroRNA-143 is a critical regulator of cell cycle activity in stem cells with co-overexpression of Akt and angiopoietin-1 via transcriptional regulation of Erk5/cyclin D1 signaling. Cell Cycle 2012;11:767-77. [PMID: 22374674 DOI: 10.4161/cc.11.4.19211] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
13 Haiart S, Watson DI, Leong MP, Astill D, Bright T, Hussey DJ. MicroRNA-196a & microRNA-101 expression in Barrett's oesophagus in patients with medically and surgically treated gastro-oesophageal reflux. BMC Res Notes 2011;4:41. [PMID: 21352563 DOI: 10.1186/1756-0500-4-41] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
14 Fassan M, Volinia S, Palatini J, Pizzi M, Baffa R, De Bernard M, Battaglia G, Parente P, Croce CM, Zaninotto G, Ancona E, Rugge M. MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer. 2011;129:1661-1670. [PMID: 21128279 DOI: 10.1002/ijc.25823] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 7.9] [Reference Citation Analysis]
15 Fassan M, Croce CM, Rugge M. miRNAs in precancerous lesions of the gastrointestinal tract. World J Gastroenterol 2011; 17(48): 5231-5239 [PMID: 22219591 DOI: 10.3748/wjg.v17.i48.5231] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
16 Gordon LG, Hirst NG, Mayne GC, Watson DI, Bright T, Cai W, Barbour AP, Smithers BM, Whiteman DC, Eckermann S; Australian Cancer Study Clinical Follow-Up Study. Modeling the Cost-effectiveness of Strategies for Treating Esophageal Adenocarcinoma and High-grade Dysplasia. J Gastrointest Surg 2012;16:1451-61. [DOI: 10.1007/s11605-012-1911-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
17 Levert-Mignon A, Bourke MJ, Lord SJ, Taylor AC, Wettstein AR, Edwards M, Botelho NK, Sonson R, Jayasekera C, Fisher OM, Thomas ML, Macrae F, Hussey DJ, Watson DI, Lord RV. Changes in gene expression of neo-squamous mucosa after endoscopic treatment for dysplastic Barrett's esophagus and intramucosal adenocarcinoma. United European Gastroenterol J 2017;5:13-20. [PMID: 28405317 DOI: 10.1177/2050640616650794] [Reference Citation Analysis]
18 Li SQ, Wang HM, Cao XF. Potential clinical insights into microRNAs and their target genes in esophageal carcinoma. Biomarkers 2011;16:629-36. [DOI: 10.3109/1354750x.2011.608132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
19 Frauenfelder C, Woods C, Hussey D, Ooi E, Klebe S, Carney AS. Aquaporin expression profiles in normal sinonasal mucosa and chronic rhinosinusitis. Int Forum Allergy Rhinol 2014;4:901-8. [PMID: 25243928 DOI: 10.1002/alr.21415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Phillips WA, Lord RV, Nancarrow DJ, Watson DI, Whiteman DC. Barrett's esophagus. J Gastroenterol Hepatol. 2011;26:639-648. [PMID: 21166712 DOI: 10.1111/j.1440-1746.2010.06602.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
21 Li SQ, Chen FJ, Cao XF. Distinctive microRNAs in esophageal tumor: early diagnosis, prognosis judgment, and tumor treatment. Dis Esophagus 2013;26:288-98. [PMID: 22458808 DOI: 10.1111/j.1442-2050.2012.01346.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
22 Mouillet JF, Chu T, Sadovsky Y. Expression patterns of placental microRNAs. Birth Defects Res A Clin Mol Teratol 2011;91:737-43. [PMID: 21425434 DOI: 10.1002/bdra.20782] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 6.4] [Reference Citation Analysis]
23 Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA expression signatures during malignant progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013;6:196-205. [PMID: 23466817 DOI: 10.1158/1940-6207.capr-12-0276] [Cited by in Crossref: 72] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
24 Akagi I, Miyashita M, Ishibashi O, Mishima T, Kikuchi K, Makino H, Nomura T, Hagiwara N, Uchida E, Takizawa T. Relationship between altered expression levels of MIR21, MIR143, MIR145, and MIR205 and clinicopathologic features of esophageal squamous cell carcinoma. Dis Esophagus. 2011;24:523-530. [PMID: 21453382 DOI: 10.1111/j.1442-2050.2011.01177.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
25 Kresty LA, Clarke J, Ezell K, Exum A, Howell AB, Guettouche T. MicroRNA alterations in Barrett's esophagus, esophageal adenocarcinoma, and esophageal adenocarcinoma cell lines following cranberry extract treatment: Insights for chemoprevention. J Carcinog 2011;10:34. [PMID: 22279419 DOI: 10.4103/1477-3163.91110] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
26 Owens VL, Katzka DA, Lutzke LS, Wang KK, Smyrk TC. Endoscopic ablative therapy for Barrett's esophagus: a potential cause of eosinophilic esophagitis. Dis Esophagus 2012;25:33-9. [PMID: 21668572 DOI: 10.1111/j.1442-2050.2011.01214.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
27 Kalogirou C, Spahn M, Krebs M, Joniau S, Lerut E, Burger M, Scholz CJ, Kneitz S, Riedmiller H, Kneitz B. MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer. Int J Mol Sci 2013;14:21414-34. [PMID: 24173237 DOI: 10.3390/ijms141121414] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]